Merus (MRUS) investor relations material

Platform and pipeline overview

• Focus on oncology with multiple clinical assets, including partnerships with Incyte, Lilly, and Gilead.

• Platform enables development of bispecific and multispecific antibodies using established monoclonal antibody processes.

• Technology leverages standard manufacturing and IgG engineering for immune engagement.

• Three out of four clinical-stage assets show improved clinical success rates.

• BIZENGRI approved last year; petosemtamab is a key focus for head and neck and colorectal cancers.

Petosemtamab in colorectal cancer

• Petosemtamab is a bispecific antibody targeting EGFR and LGR5, with strong preclinical rationale for colorectal cancer.

• Early phase 1 data in heavily pretreated patients showed no responses; current studies focus on earlier lines and genetically wild-type populations.

• Safety profile is favorable, with manageable infusion-related reactions and fewer severe events than similar therapies.

• Clinical update for colorectal cancer cohorts expected in the second half of the year.

• Benchmarks for efficacy are based on cetuximab response rates: ~65% first-line, ~30% second-line.

Petosemtamab in head and neck cancer

• Phase 1/2 data show a 63% response rate in first-line combination with pembrolizumab, nearly tripling standard rates.

• One-year survival rate approaches 80%, unprecedented in this setting.

• Second-line data show a 36% response rate and median survival of 12.5 months, outperforming standard therapies.

• Breakthrough therapy designation granted by FDA for both first- and second-line settings.

• Safety profile remains favorable, with no amplified toxicities in combination regimens.